JP2010522141A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522141A5
JP2010522141A5 JP2009546461A JP2009546461A JP2010522141A5 JP 2010522141 A5 JP2010522141 A5 JP 2010522141A5 JP 2009546461 A JP2009546461 A JP 2009546461A JP 2009546461 A JP2009546461 A JP 2009546461A JP 2010522141 A5 JP2010522141 A5 JP 2010522141A5
Authority
JP
Japan
Prior art keywords
molecule
seq
chain variable
variable region
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009546461A
Other languages
English (en)
Japanese (ja)
Other versions
JP5307030B2 (ja
JP2010522141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050554 external-priority patent/WO2008088983A1/en
Publication of JP2010522141A publication Critical patent/JP2010522141A/ja
Publication of JP2010522141A5 publication Critical patent/JP2010522141A5/ja
Application granted granted Critical
Publication of JP5307030B2 publication Critical patent/JP5307030B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009546461A 2007-01-18 2008-01-09 ＰＥＧ化ＡβＦＡＢ Expired - Fee Related JP5307030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88543907P 2007-01-18 2007-01-18
US60/885,439 2007-01-18
PCT/US2008/050554 WO2008088983A1 (en) 2007-01-18 2008-01-09 PEGYLATED Aβ FAB

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013133551A Division JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Publications (3)

Publication Number Publication Date
JP2010522141A JP2010522141A (ja) 2010-07-01
JP2010522141A5 true JP2010522141A5 (OSRAM) 2011-02-10
JP5307030B2 JP5307030B2 (ja) 2013-10-02

Family

ID=39332186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009546461A Expired - Fee Related JP5307030B2 (ja) 2007-01-18 2008-01-09 ＰＥＧ化ＡβＦＡＢ
JP2013133551A Expired - Fee Related JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013133551A Expired - Fee Related JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Country Status (26)

Country Link
US (1) US8066999B2 (OSRAM)
EP (2) EP2842967B1 (OSRAM)
JP (2) JP5307030B2 (OSRAM)
KR (2) KR101160385B1 (OSRAM)
CN (2) CN103479998B (OSRAM)
AR (1) AR064944A1 (OSRAM)
AU (1) AU2008206555B2 (OSRAM)
BR (1) BRPI0806715A2 (OSRAM)
CA (1) CA2675847C (OSRAM)
CL (1) CL2008000121A1 (OSRAM)
CY (2) CY1116157T1 (OSRAM)
DK (1) DK2121754T3 (OSRAM)
EA (1) EA020979B1 (OSRAM)
ES (2) ES2615454T3 (OSRAM)
HR (2) HRP20150237T1 (OSRAM)
IL (2) IL199838A (OSRAM)
LT (1) LT2842967T (OSRAM)
MX (1) MX2009007691A (OSRAM)
PE (1) PE20081634A1 (OSRAM)
PL (1) PL2121754T3 (OSRAM)
PT (2) PT2842967T (OSRAM)
RS (1) RS53948B1 (OSRAM)
SI (2) SI2121754T1 (OSRAM)
TW (1) TW200836763A (OSRAM)
UA (1) UA95996C2 (OSRAM)
WO (1) WO2008088983A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170116193A (ko) 2008-06-20 2017-10-18 노파르티스 아게 응집이 감소된 면역글로불린
PT2310970E (pt) 2008-06-20 2013-07-26 Massachusetts Inst Technology Métodos de identificação de regiões de ligação macromolecular e de regiões predispostas à agregação nas proteínas e suas utilizações
AU2010256410B2 (en) * 2009-06-04 2016-10-20 Massachusetts Institute Of Technology Methods for identification of sites for IgG conjugation
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2015036553A1 (en) * 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
CN109562167A (zh) 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CA3070085A1 (en) 2017-07-18 2019-01-24 Promis Neurosciences Inc. Antibodies to amyloid beta
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019134039A1 (en) * 2018-01-04 2019-07-11 Septa Therapeutics, Inc. Septapeptides associated with neurodegeneracy
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2182731A1 (en) * 1994-02-03 1995-08-10 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5668651A (en) * 1994-03-18 1997-09-16 Sharp Kabushiki Kaisha Polymer-wall LCD having liquid crystal molecules having a plane-symmetrical bend orientation
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
WO1998044955A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6227999B1 (en) 1997-07-09 2001-05-08 Transmisiones Tsp, S.A. De C.V. Method and apparatus for operating a clutch in an automated mechanical transmission
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
AU8777898A (en) * 1997-08-11 1999-03-01 Chiron Corporation Methods for genetically modifying t cells
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
WO1999060024A1 (en) 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
ATE405636T1 (de) * 1999-06-16 2008-09-15 Boston Biomedical Res Inst Immunologische kontrolle des beta-amyloid gehaltes in vivo
EP1200470B1 (en) 1999-08-04 2004-11-24 The University Of Southern California Globular assembly of amyloid beta protein and uses thereof
CA2349434A1 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
KR100653153B1 (ko) 1999-12-22 2006-12-01 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체의 입체장애 유도체
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU2001290638C1 (en) 2000-09-06 2009-04-30 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1944040B1 (en) * 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
CA2452104A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2003015691A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
WO2003015617A2 (en) 2001-08-17 2003-02-27 Washington University Assay method for alzheimer's disease
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
JP2005523335A (ja) 2002-04-25 2005-08-04 イーライ・リリー・アンド・カンパニー 高齢被検体の不安障害および気分障害の治療方法
KR101025143B1 (ko) * 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
CA2529819A1 (en) * 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
US20080107601A1 (en) * 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION

Similar Documents

Publication Publication Date Title
JP2010522141A5 (OSRAM)
HRP20161677T1 (hr) Pegilirani fab protiv amiloida beta
HRP20170110T1 (hr) Monoklonska protutijela
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2014505463A5 (OSRAM)
CY1113630T1 (el) Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn
JP2013524774A5 (OSRAM)
CY1120014T1 (el) Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες
JP2013525266A5 (OSRAM)
IL319612A (en) Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
HRP20200036T1 (hr) Postupci liječenja tauopatije
RU2534564C3 (ru) Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
JP2006522830A5 (OSRAM)
JP2011528561A5 (OSRAM)
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
MX2009009226A (es) Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
WO2010012004A3 (en) Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
JP2010202664A5 (OSRAM)
JP2010514779A5 (OSRAM)
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
JP2006506942A5 (OSRAM)
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
JP2010513327A5 (OSRAM)
JP2007516193A5 (OSRAM)